^
Association details:
Biomarker:IGF1R expression
Cancer:Thymic Carcinoma
Drug:everolimus (mTOR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Title:

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Published date:
02/01/2018
Excerpt:
Patients received oral everolimus 10 mg/d...Immunohistochemical positivity for p4E-BP1 or insulin-like growth factor-1 receptor was statistically significantly related to a shorter survival.
DOI:
10.1200/JCO.2017.74.4078
Trial ID: